Member Directory - TB Working Group

Chair: Susan Swindells

Objectives:

  • Guide product development and identify knowledge gaps requiring further research and resources for the prevention and treatment of tuberculosis (TB). Our goal is to identify the most promising drug candidates for development as long-acting/extended release (LA/ER) formulations.
  • Promote the development of LA/ER approaches for TB by building on previous modelling and preclinical work to evaluate novel long-acting formulations of TB drugs.
  • Develop additional applications to understand if in silico modelling can predict important drug-drug interactions involving LA/ER formulations, a particularly relevant issue for HIV and TB drugs where rifamycins are the source of many complex and significant interactions. Models will also be improved to provide dosing strategies for infants, children, adolescents, and pregnant women.

Interested in joining?
Please submit your request and your CV to Ana Cervantes. Acceptance requires a written nomination from a TB Working Group member and majority approval.

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.

Conflict of Interest: Dr. Swindells reports research grants to her institution from ViiV Healthcare.

Nicole Ammerman is a Research Associate in the Department of Medicine, Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. 

Conflict of Interest:  No real or apparent conflicts of interest to report.

Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research.

Conflict of Interest: My spouse owns stock in Merck.  I have consulted for Sanofi.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. 

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y.

Conflict of Interest: None disclosed.

Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB.

Conflict of Interest:  I have research grants and contracts from Janssen, TB Alliance and the Gates Medical Research Institute in addition to NIH.

David has >20 years of infectious disease drug discovery experience with a focus on HIV-1 and HCV.

Conflict of Interest: 

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. 

Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare

Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Pharmaceutical Advocate to Médecins Sans Frontières on specific dossiers, such as access to Tuberculosis medicines.

Conflict of Interest: No real or apparent conflicts of interest to report.

Manuele Piccolis holds a PhD in Life Sciences from the University of Geneva and he has an extensive experience in metabolism.

Conflict of Interest: No disclosures

Dr. Podany is currently an Assistant Professor in the department of pharmacy practice at the University of Nebraska Medical Center.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom.

Conflict of Interest: No real or apparent conflicts of interest to report.

Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994.

Conflict of Interest: As a Janssen employee I have a wage and shares from/in the company.

Kimberly Scarsi is an Associate Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr Marco Siccardi graduated with an MSc in Clinical Biology (2006) at the University of Turin, Italy. 

Conflict of Interest: I received research grants from Janssen and ViiV. I also serve as a consultant to Merck, Resolution Therapeutics and Nevakar Inc.